RB1 and metastatic neoplasm: RB1 encoding the Rb protein is characterized above (Figure 2).[18] At the time of referral to the CCTT the patient had metastatic disease to her lungs, mediastinum and liver and subsequently received experimental therapy with hepatic arterial infusion oxaliplatin (140 mg/m2 every 3 weeks), intravenous bevacizumab (10 mg/kg every 3 weeks) and oral capecitabine (1500 mg/m2 on days 1-4 every 3 weeks) and was taken off therapy after 2.9 months because of poor tolerance.